Kanghong Pharmaceuticals: Brilacidine tablets receive drug registration certificate.

Kanghong Pharmaceuticals announces that recently it has received the Drug Registration Certificate for Brexpiprazole issued by the National Medical Products Administration, approving its registration. The mechanism of action of Brexpiprazole for the treatment of schizophrenia is not yet clear, but it may involve partial agonist activity at 5-HT1A and D2 dopamine receptors, as well as antagonist activity at 5-HT2A receptors. The approval of Brexpiprazole tablets for marketing enriches the company's product pipeline.